Alcon—the eye-focused pharma spun out of Novartis—is handing over $550 million to buy out Neurotech Pharmaceuticals, its ...

Recruiting an industry veteran to steer the company through its darkest hour of growth pressures, CSL has hired GSK’s Deborah ...

As policies from the last two presidential administrations put heightened focus on drug affordability in the United States, a ...

In its own approval announcement on Oct. 20, the FDA hailed Hibsago as a “first-of-its-kind” treatment in chronic hepatitis B ...

Many direct-to-patient (DTP) programs have significantly affected access to medicines, a survey of U.S. | Many direct-to-patient programs have significantly affected access to medicines, a survey of U ...

With the win fleshed out, AZ and Amgen are now eyeing regulatory filings to carve out a potential third indication for ...

The FDA is codifying its regulations around mobile apps that go along with prescription drugs, offering a clearer framework ...

Veradermics is keeping pace in an already high-octane year.  | Topline results show the biotech's lead asset, VDPHL01, ...

Next-gen manufacturer Antheia is teaming up with the U.S. Department of War to build out its infrastructure and onshore the U.S. drug supply chain.  | The Department of War is allotting a conditional ...

Cosette Pharmaceuticals has achieved a corporate milestone, securing an FDA approval for a legacy Daiichi Sankyo drug in its ...

AbbVie has formed a multiyear deal with the McLaren Formula 1 team, signing up to raise awareness of immune-mediated diseases ...

Eli Lilly is betting on a pediatric expansion to give it’s IL-23p19 inhibitor Omvoh an edge in the fiercely competitive ...